Oncology

News

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

News

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.

News

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

News

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

News

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

News

Aktis Oncology has filed its IPO, seeking to raise up to around $210 million in what could be the first biotech listing on the Nasdaq in 2026.